Suven Gets Two Japanese Patents

According to the invention 4460446 patent disclosure, the compounds are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.

With these a total of three Japanese product patents are granted to Suven. The granted claims of the patent include the class of selective Serotonin receptor affinity compounds discovered by Suven and are being developed as therapeutic agents.

There are several product patent applications from Suven Discovery Research are in the pipeline and Suven secured intellectual property protection for several of their NCEs in all major markets like US, Canada, Europe, China, Russia, India, Japan, Australia, New Zealand, Brazil and Mexico.

Suvan said that these granted patents are exclusive intellectual property of it and are achieved through the internal drug discovery research efforts. Products out of these inventions may be out-licensed at the stage of clinical Phase-1 or Phase-II.

Venkat Jasti, CEO of Suven, said: “We are very pleased by the grant of these patents to Suven by Japanese Patent Office for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $20bn market potential globally”